INTRODUCTION
============

Hepatocellular carcinoma (HCC) is the one of the worst malignancies, where mortality (781,631 deaths) closely parallels incidence (841,080 cases diagnosed) \[[@b1-cmh-2019-0021n]-[@b3-cmh-2019-0021n]\]. Frequent surveillance is recommended for the high-risk population of patients with HCC, such as those with cirrhosis or hepatitis virus infection, to diagnose the disease at an early stage \[[@b2-cmh-2019-0021n]-[@b8-cmh-2019-0021n]\]. Patients with limited tumor burden with well liver function are the best candidates for resection. Another alternative treatment option for those with up to three nodules or nodules 3 cm or smaller (without both macrovascular invasion \[MVI\] and extrahepatic metastasis \[EHM\]) is local ablation therapy (radiofrequency ablation or microwave ablation) \[[@b3-cmh-2019-0021n]-[@b8-cmh-2019-0021n]\]. All over the world, the first-line treatment widely recommended for unresectable HCC without both MVI and EHM is transarterial chemoembolization (TACE), which is a locoregional treatment \[[@b3-cmh-2019-0021n]-[@b8-cmh-2019-0021n]\]. Novel molecular target therapies have been proven the effectiveness in phase 3 studies, and thus, several treatment options have become standard systemic therapies for advanced-stage HCC or for those tumors progressing to locoregional treatment \[[@b9-cmh-2019-0021n]-[@b14-cmh-2019-0021n]\]. However, creating a distinct definition of the timing of switching from locoregional treatment to systemic therapies in patients with HCC is not easy. Thus far, consultation with experts with advanced knowledge is needed when deciding to give up locoregional treatment and switching to systemic therapies in the field. Therefore, the aims of this study were to review the efficacy and limitations of TACE and discuss the most appropriate timing for switching from locoregional treatment to systemic therapies.

RECONSIDERATION OF TACE FROM THE CURRENT PERSPECTIVE
====================================================

TACE is the most widely used treatment worldwide for unresectable HCC \[[@b2-cmh-2019-0021n],[@b3-cmh-2019-0021n],[@b15-cmh-2019-0021n]\]. The Bridge to Better Outcomes in HCC (BRIDGE) study, an international large and longitudinal cohort study that included 18,031 patients in 14 countries, indicated that TACE was frequently performed not only for patients with intermediate-stage HCC but also for patients with early- or advanced-stage HCC according to the Barcelona Clinic Liver Cancer (BCLC) staging system \[[@b15-cmh-2019-0021n]\]. Looking back at the history of TACE, improved patient survival with TACE compared with best supportive care or suboptional treatments was demonstrated by a meta-analysis of six randomized controlled trials in 2003 \[[@b16-cmh-2019-0021n]\]. Therefore, both Eastern and Western guidelines have recommended TACE as therapy in patients with intermediate-stage HCC ([Table 1](#t1-cmh-2019-0021n){ref-type="table"}) \[[@b4-cmh-2019-0021n]-[@b8-cmh-2019-0021n]\]. So far, there are two major TACE techniques, namely, conventional TACE (cTACE), which uses a lipiodol mixture with chemotherapy agents, and TACE with drug-eluting bead (DEB-TACE) \[[@b17-cmh-2019-0021n]-[@b24-cmh-2019-0021n]\]. In one randomized controlled trial comparing cTACE and DEB-TACE, no difference was found in tumor response and time to progression \[[@b24-cmh-2019-0021n]\]. The decision whether to undergo cTACE or DEB-TACE seems to be dependent on the medical situation of each country or the institution.

Institutions with a high volume of patients or substantial experiences have advanced TACE techniques \[[@b20-cmh-2019-0021n],[@b25-cmh-2019-0021n]-[@b28-cmh-2019-0021n]\]. So far, cone-beam or interventional radiology angiography computed tomography systems can construct three-dimensional reconstruction of arteries and support superselective TACE \[[@b29-cmh-2019-0021n]-[@b31-cmh-2019-0021n]\]. Moreover, inserting a catheter into the tumor feeding arteries superselectively leads to the prevention of liver function and reduction in negative side effects. Using a large cohort of patients (n=815), Yamakado et al. \[[@b32-cmh-2019-0021n]\] reported that selective TACE contributed to survival outcomes in patients who received TACE (hazard ratio, 0.68; 95% confidence interval, 0.48--0.97; *P*=0.033). Another systemic review indicated that the most common adverse events were related to the postembolization syndrome, including increased liver enzyme (18.1%), fever (17.2%), abdominal pain (11.0%), vomiting (6.0%), and nausea (1.7%) \[[@b20-cmh-2019-0021n]\]. In a recent randomized placebo-controlled trial \[[@b33-cmh-2019-0021n]\], it was that indicated prophylactic dexamethasone prevented postembolization syndrome, although validation is required. Current treatment-related death rate is estimated to be less than 1% in patients with HCC.

A latest systemic review that had, to date, more than 10,000 patients with HCC undergoing TACE documented a 52.3% objective response, with overall 1-, 2-, 3-, and 5-year survival rates of 70.3%, 51.8%, 40.4%, and 32.4%, respectively \[[@b20-cmh-2019-0021n]\]. Nowadays, the median overall survival (OS) of patients with intermediate-stage HCC who received TACE is suggested to be around 30 months \[[@b2-cmh-2019-0021n]\]. In more than half of patients, objective response can be achieved by TACE, and tumor progression may be delayed in these patients \[[@b10-cmh-2019-0021n]\]. However, a latest international observation study (the outcomes of HCC patients treated with TACE and early, not early or not at all followed by sorafenib \[OPTIMIS\] study) found that with repeated TACE, expectation rates of objective response decreased (first TACE: 40%; second TACE: 26%; third TACE: 24%; and fourth TACE: 25%) \[[@b34-cmh-2019-0021n]\].

A recent report based on a US database (n=3,967) \[[@b35-cmh-2019-0021n]\] demonstrated deterioration of liver function from baseline in the acute period, which persisted in the chronic period (bilirubin, 30% and 23%; albumin, 52% and 31%; aspartate transaminase, 44% and 25%; alanine transaminase, 43% and 25%; and prothrombin time, 25% and 15%, respectively). Hiraoka et al. \[[@b36-cmh-2019-0021n]\], using a Japanese multicenter cohort, reported that liver function deteriorated with repeated TACE. It is well known that in patients with HCC, retaining liver function is equally important as removing or controlling tumor \[[@b36-cmh-2019-0021n]\]. That is, it is possible to experience decreasing liver function without getting an objective response when continuing TACE without appropriate decisions.

WHAT IS "TACE REFRACTORY"?
==========================

In most cases of unresectable HCC, before the use of sorafenib was approved, treatment with TACE was continued casually. Repeated TACE is associated with increased liver failure and diminishing efficacy. If treatment with TACE is continued without any assessment, the patient loses the opportunity to convert to systemic therapy because of liver function deterioration \[[@b37-cmh-2019-0021n]\]. Regarding recommendations or suggestions for patients with unresectable HCC to switch from TACE to systemic therapies, "TACE refractory" is a new-era concept that has been advocated since sorafenib was first used in practice ([Table 2](#t2-cmh-2019-0021n){ref-type="table"}) \[[@b4-cmh-2019-0021n],[@b5-cmh-2019-0021n],[@b38-cmh-2019-0021n]-[@b41-cmh-2019-0021n]\]. It has been suggested that the appropriate timing of switching from TACE to systemic therapies is when repeated TACE is expected to become ineffective, the so-called TACE refractory. Kudo et al. \[[@b38-cmh-2019-0021n],[@b39-cmh-2019-0021n]\], from Japan, published one of the major suggestions on this topic. Their recommendation was validated in two retrospective studies that showed that patients with intermediate-stage HCC whose disease was refractory to TACE and who switched to sorafenib had prolonged OS compared with those who continued TACE (first trial: 25.4 vs. 11.5 months, *P*=0.003; second trial: 24.7 vs. 13.6 months, *P*=0.002) \[[@b42-cmh-2019-0021n],[@b43-cmh-2019-0021n]\]. Currently, a large cohort global prospective observation study (OPTIMIS) confirmed that compared with other treatments, switching to sorafenib immediately after TACE ineligibility improved OS (propensity score matched cohort: 15.2 vs. 11.8 months) \[[@b34-cmh-2019-0021n]\].

Regarding liver function, one Japanese study confirmed that liver function was not preserved with continuing TACE treatment after TACE refractory; patients with TACE refractory who continued to receive TACE had a significantly shorter median time to liver dysfunction than did those who switched to sorafenib (17.0 vs. 29.8 months, *P*=0.030) \[[@b42-cmh-2019-0021n]\]. In another other study, patients with TACE refractory who underwent repeated TACE had a greater increase in Child-Pugh score compared with patients who were converted to sorafenib \[[@b43-cmh-2019-0021n]\]. Taken together, these two studies strongly suggest that repeated TACE leads to deterioration in liver function in patients who are deemed refractory to TACE.

WHY IS "TACE REFRACTORY" EMPHASIZED NOW?
========================================

At present, phase 3 trials have proven the statistical significance of five molecular target agents as both first-line (sorafenib and lenvatinib) and second-line (regorafenib, ramcirumab, and cabozantinib) treatments for patients with HCC \[[@b9-cmh-2019-0021n]-[@b14-cmh-2019-0021n]\]. These drugs have been approved worldwide. Moreover, on the basis of early-phase trials, the US Food and Drug Administration also approved two immune checkpoint inhibitors (nivolumab and pembrolizumab) \[[@b44-cmh-2019-0021n],[@b45-cmh-2019-0021n]\]. Looking back at the results of the phase 3 trials in patients with HCC, both the testing and control arms had increased median OSs during the previous decade as a result of the treatments after progression \[[@b9-cmh-2019-0021n],[@b10-cmh-2019-0021n],[@b14-cmh-2019-0021n],[@b46-cmh-2019-0021n],[@b47-cmh-2019-0021n]\]. In the study of regorafenib after sorafenib in patients with HCC (RESORCE) trial, Finn et al. \[[@b48-cmh-2019-0021n]\] reported a median OS of 26.0 months for the regorafenib arm from the time sorafenib was started, although the included population in the trial was limited because of strict inclusion criteria. Several retrospective studies have reported that sequential therapies might have an impact on the survival of patients with advanced HCC \[[@b49-cmh-2019-0021n],[@b50-cmh-2019-0021n]\]. In the next era, a major strategy in patients with HCC seems to be sequential treatment with systemic therapies, although different countries or regions have different regulations regarding the use of each drug. That being said, in TACE refractory patients, survival outcomes with systemic therapies are suggested to be longer than with treatment with a single agent, like sorafenib.

Moreover, when considering using two or more molecular target agents in the clinical treatment of identical patients with HCC, we should focus on maintaining liver function more than we did in the previous era. Liver function deterioration leads to missed opportunities to start or switch to systemic therapies. Several latest reports have demonstrated that the high-tumor-burden population of patients with intermediate-stage HCC (large size or/and a lot of nodules) were at high risk of liver function deterioration after TACE \[[@b51-cmh-2019-0021n]-[@b53-cmh-2019-0021n]\]. Two retrospective studies, which criticized the Japan Society of Hepatology's definition of TACE refractory, reported that 20--25% of patients had decreased liver function and Child-Pugh class B or C at the time they were deemed TACE refractory even though they were determined to have Child-Pugh class A at the time of initial TACE \[[@b42-cmh-2019-0021n],[@b43-cmh-2019-0021n]\]. Taken together, the optimal timing to convert from TACE to systemic therapies may be when the patient's condition becomes unstable, which is different among individuals based on each patient's tumor status, treatment outcome of previous TACE and hepatic spare ability.

Recently, Kudo et al. \[[@b54-cmh-2019-0021n]\] compared survival outcomes between TACE and lenvatinib in seven patients with intermediate-stage HCC by using the propensity score matching method. In this study, the lenvatinib group had no history of receiving TACE. Despite the presence of several biases, the result might suggest the possibility that systemic therapies can become the initial treatment choice and may replace TACE in a limited population of patients with intermediate-stage HCC. A randomized controlled trial that compares systemic therapy and TACE will be carried out in the near future.

STOP AND THINK CAREFULLY BEFORE PROCEEDING TO EACH TACE
=======================================================

With the development of novel compounds and the improving survival outcomes of patients with HCC, current systemic therapies should be considered as a treatment option for unresectable HCC. Especially in patients with intermediate-stage HCC, who can expect long clinical courses with better prognosis compared with advanced-stage HCC, updated treatment strategies with multimolecular agents focusing on not only short-term outcomes but also foresight with long-term perspectives are required. A validity assessment of the TACE procedure should be recommended before proceeding to each TACE ([Fig. 1](#f1-cmh-2019-0021n){ref-type="fig"}). In cases where the effectiveness of TACE is not expected or chronic liver function deterioration may occur after TACE, conversion to systemic therapies should be considered. Although the definition of TACE refractory by the Japan Society of Hepatology is useful information, switching the timing of TACE to way before the patient's liver function deteriorates, taking into account both the high expectations of clinical outcome with current sequential therapies of molecular target agents and preventing hepatic spare abilities, may be better. Radiologists, who have the responsibility for TACE, and hepatologists or oncologists should communicate more closely and construct treatment strategies for patients with unresectable HCC who receive TACE with a view of the prospect to convert from TACE to systemic therapies.

CONCLUSIONS
===========

The present guidelines recommend TACE as first-line treatment for patients with unresectable HCC without both MVI and EHM. Several novel compounds have shown survival benefits in patients with advanced HCC. Nowadays, sequential therapies with two or more agents have prolonged patients' survival outcomes and have become predominant treatment strategies among patients with HCC. The anticipated clinical impact of systemic therapies in patients with HCC has increased, and conversion from TACE to systemic therapies is now weighed more heavily. Before starting treatment with TACE, conversion to systemic therapies or not should be considered ("Stop and think carefully before proceeding to each TACE"). Looking ahead to the future of systemic therapies, it is now necessary to foster a greater understanding of preserving liver function during TACE treatments.
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###### 

Recommendations for transarterial chemoembilization in guidelines all over the world

  Guidelines                                                                                     Recommendations
  ---------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Asian Pacific Association for the Study of the Liver (APASL) (2017) \[[@b4-cmh-2019-0021n]\]   First line in patients with unresectable, large multifocal HCCs, without vascular invasion or extrahepatic spread.
  European Association for the Study of the Liver (EASL) (2018) \[[@b6-cmh-2019-0021n]\]         First line in BCLC B patients (not recommended for patients with decompensated liver disease, advanced liver and/or kidney dysfunction, macroscopic vascular invasion, or extrahepatic spread).
  Korean Liver Cancer Association-National Cancer Center Korea (2019) \[[@b7-cmh-2019-0021n]\]   Patients with a good performance status without major vascular invasion or extrahepatic spread who are ineligible for surgical resection and liver transplantation, RFA, or PEIT.
  Japan Society of Hepatology (JSH) (2019) \[[@b8-cmh-2019-0021n]\]                              Unresectable Child-Pugh A and B patients with one to three nodules (≥3 cm) and more than four nodules (any size), without both vascular invasion and extrahepatic metastasis.

HCC, hepatocellular carcinoma; BCLC, Barcelona Clinic Liver Cancer; RFA, radiofrequency ablation; PEIT, percutaneous ethanol injection therapy.

###### 

Recommendations/suggestions for switching from transarterial chemoembilization to systemic therapies in patients with unresectable hepatocellular carcinoma without both macrovascular invasion and extrahepatic metastasis

  Guidelines/articles                                                                                                   Recommendations/suggestions
  --------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Raoul et al. \[[@b40-cmh-2019-0021n]\] (2011)                                                                         Patients who progress after two cycles of TACE
  JSH-LCSGJ criteria 2014 (so-called the definition of TACE failure/refractoriness) (2014) \[[@b39-cmh-2019-0021n]\]    \(1\) Intrahepatic lesion
  •                                                                                                                     Two or more consecutive insufficient responses of the treated tumor (viable lesion \>50%) even after changing the chemotherapeutic agents and/or reanalysis of the feeding artery seen on response evaluation CT/MRI at 1--3 months after having adequately performed selective TACE
  •                                                                                                                     Two or more consecutive progressions in the liver (tumor number increases as compared with tumor number before the previous TACE procedure) even after having changed the chemotherapeutic agents and/or reanalysis of the feeding artery seen on response evaluation CT/MRI at 1--3 months after having adequately performed selective TACE
  \(2\) Continuous elevation of tumor makers immediately after TACE even though slight transient decrease in observed   
  \(3\) Appearance of vascular invasion                                                                                 
  \(4\) Appearance of extrahepatic spread                                                                               
  Asian Pacific Association for the Study of the Liver (APASL) (2017) \[[@b4-cmh-2019-0021n]\]                          Treatment conversion from TACE to systemic therapy is recommended for patients in whom TACE is expected to be insufficient.
  Galle et al. \[[@b41-cmh-2019-0021n]\] (2017)                                                                         Patients who have never or no longer respond to TACE (treatment stage migration to the righthand side on the BCLC staging system).
  American Association for Study of Liver Disease (AASLD) (2018) \[[@b5-cmh-2019-0021n]\]                               Patients who are ineligible for or progress after TACE/TARE should be considered for systemic therapy.
  Japan Society of Hepatology (JSH) (2019) \[[@b8-cmh-2019-0021n]\]                                                     Molecular target therapy is recommended as second-line therapy for up to four intrahepatic nodules.

TACE, transarterial chemoembolization; CT, computed tomography; MRI, magnetic resonance imaging; BCLC, Barcelona Clinic Liver Cancer; TARE, transarterial radioembolization.
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